Common Contracts
7 similar Underwriting Agreement contracts by Northern Oil & Gas, Inc., Eleven Biotherapeutics, Inc., Ambrx Inc, Discovery Laboratories Inc /De/
NORTHERN OIL AND GAS, INC. 6,500,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 13th, 2023 • Northern Oil & Gas, Inc. • Crude petroleum & natural gas • New York
Northern Oil and Gas, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereof (the “Underwriters”) for whom you are acting as representative (the “Representative”) an aggregate of 6,500,000 shares (the “Firm Shares”) of the common stock, par value $0.001 per share, of the Company (“Common Stock”). The Company also proposes to grant to the Underwriters an option to purchase up to 975,000 additional shares of Common Stock (the “Option Shares”) as set forth in Section 2 hereof. The Firm Shares and the Option Shares are herein collectively referred to as the “Shares.”
NORTHERN OIL AND GAS, INC. 5,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 21st, 2021 • Northern Oil & Gas, Inc. • Crude petroleum & natural gas • New York
Northern Oil and Gas, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representative (the “Representative”) an aggregate of 5,000,000 shares (the “Firm Shares”) of the common stock, par value $0.001 per share, of the Company (“Common Stock”). The Company also proposes to grant to the Underwriters an option to purchase up to 750,000 additional shares of Common Stock (the “Option Shares”) as set forth in Section 2 hereof. The Firm Shares and the Option Shares are herein collectively referred to as the “Shares.”
NORTHERN OIL AND GAS, INC. 12,500,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2021 • Northern Oil & Gas, Inc. • Crude petroleum & natural gas • New York
Northern Oil and Gas, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representative (the “Representative”) an aggregate of 12,500,000 shares (the “Firm Shares”) of the common stock, par value $0.001 per share, of the Company (“Common Stock”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,875,000 additional shares of Common Stock (the “Option Shares”) as set forth in Section 2 hereof. The Firm Shares and the Option Shares are herein collectively referred to as the “Shares.”
•] Shares of Common Stock (or Pre-Funded Warrants to Purchase Shares of Common Stock in Lieu Thereof) and Warrants to Purchase [•] Shares of Common Stock Eleven Biotherapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 31st, 2017 • Eleven Biotherapeutics, Inc. • Pharmaceutical preparations • New York
Eleven Biotherapeutics, Inc. a Delaware corporation (the “Company”), proposes to issue and sell to H.C. Wainwright & Co., LLC (the “Underwriter”) (i) an aggregate of [•] (a) shares (the “Firm Shares”) of Common Stock, par value $0.01 per share, of the Company (the “Common Stock”) and (b) pre-funded warrants to purchase Common Stock in lieu thereof at an exercise price of $0.01 per share (the “Pre-Funded Warrants”); and (ii) warrants to purchase up to an aggregate of [•] shares of Common Stock (the “Firm Warrants” and collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”)). The amount and form of the Firm Securities to be purchased by the Underwriter is set forth opposite its name on Schedule I hereto. In addition, the Company proposes to grant to the Underwriter an option to purchase up to an additional [•] shares of common stock (the “Option Shares”) and/or warrants to purchase [•] shares of Common Stock (the “Option Warrants,” and together with the Opti
•] Shares of Common Stock (or Pre-Funded Warrants to Purchase Shares of Common Stock in Lieu Thereof) and Warrants to Purchase [•] Shares of Common Stock Eleven Biotherapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 30th, 2017 • Eleven Biotherapeutics, Inc. • Pharmaceutical preparations • New York
Eleven Biotherapeutics, Inc. a Delaware corporation (the “Company”), proposes to issue and sell to H.C. Wainwright & Co., LLC (the “Underwriter”) (i) an aggregate of [•] (a) shares (the “Firm Shares”) of Common Stock, par value $0.01 per share, of the Company (the “Common Stock”) and (b) pre-funded warrants to purchase Common Stock in lieu thereof at an exercise price of $0.01 per share (the “Pre-Funded Warrants”); and (ii) warrants to purchase up to an aggregate of [•] shares of Common Stock (the “Firm Warrants” and collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”)). The amount and form of the Firm Securities to be purchased by the Underwriter is set forth opposite its name on Schedule I hereto. In addition, the Company proposes to grant to the Underwriter an option to purchase up to an additional [•] shares of common stock (the “Option Shares”) and/or warrants to purchase [•] shares of Common Stock (the “Option Warrants,” and together with the Opti
] Shares AMBRX, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 3rd, 2014 • Ambrx Inc • Pharmaceutical preparations • New York
Ambrx, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of [ ] shares (the “Firm Shares”) of the common stock, par value $0.001 per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, at the option of the Underwriters, up to an additional [ ] shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares”.
25,000,000 Shares DISCOVERY LABORATORIES, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 31st, 2013 • Discovery Laboratories Inc /De/ • Biological products, (no disgnostic substances) • New York
Discovery Laboratories Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of 25,000,000 shares (the “Firm Shares”) of the common stock, par value $0.001 per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 3,750,000 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares.”
